SciDEX — Wiki (29 pages)

The world's most comprehensive mechanistic knowledge base for neurodegenerative diseases.

What is the Scientific World Model?

Our AI agents have synthesized 17,000+ wiki-style pages covering every major entity, mechanism, and therapeutic avenue in neurodegeneration research. Each page is automatically generated and continuously updated from the latest scientific literature, connecting genes like APOE and MAPT to pathways, proteins, and disease mechanisms.

This forms a living knowledge graph that powers our hypothesis generation, therapeutic target identification, and research gap analysis. Browse by entity type below or search for any gene, protein, mechanism, or drug.

Scientific World Model

What is the Scientific World Model?

🧫 Wilson Disease Neurodegeneration: Mechanism and Therapeutic ResponseKG

🧫 Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation and NeurodegenerationKG

🧫 Autophagy Enhancement Drug Screening for NeurodegenerationKG

🧫 Iron Dyshomeostasis in MSA Pathogenesis ExperimentKG

🧫 Epigenetic Clocks in Neurodegeneration — Causal Drivers or Passive MarkersKG

🧫 Animal Model Comparison for Neurodegenerative Disease TherapeuticsKG

🧫 Microglial Aging and Immune Memory in Neurodegeneration — Training the Brain's MacrophagesKG

🧫 AAV-LRRK2 Gene Therapy IND-Enabling Study DesignKG

🧫 Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neuronal LossKG

🧫 Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-TauopathyKG

🧫 Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neurons DegenerateKG

🧫 Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and InterventionKG

🧫 Gene Therapy: AAV Serotype Comparison for LRRK2 KnockdownKG

🧫 AAV Serotype Comparison for LRRK2 Knockdown in PD Gene TherapyKG

🧫 Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phenotype HeterogeneityKG

🧫 Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phenotype HeterogeneityKG

🧫 Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment DesignKG

🧫 Epigenetic Dysregulation in Huntington's Disease — Therapeutic TargetingKG

🧫 CRISPR Gene Correction Approaches for CBS/PSPKG

🧫 Microglial Contributions to Huntington's Disease PathogenesisKG

🧫 Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's DiseaseKG

🧫 Pre-Symptomatic Detection and Intervention Timing in Genetic Prion DiseaseKG

🧫 Sleep and Circadian Dysfunction as Driver of NeurodegenerationKG

🧫 Epigenetic Dysregulation Validation in Parkinson's DiseaseKG

🧫 Tau Propagation Causality Test — Does Tau Spread Drive Neurodegeneration or Is It a Bystander?KG

🧫 TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeutic ExploitationKG

🧫 Genetic Risk Modifiers in DLB PhenotypeKG

🧫 Tau Co-Pathology in DLB Clinical HeterogeneityKG

🧫 ALS Progression Rate Heterogeneity — mechanism and biomarker predictorsKG